In this section you'll find photographic features that explore holidays and photography courses, details about members meetings, trials and tribulations of installing new software along with ...

Glaukos Co. (NYSE:GKOS – Get Free Report)’s stock price traded down 6.6% during mid-day trading on Wednesday after Mizuho lowered their price target on the stock from $200.00 to $175.00.

The maker of the world’s smallest medical device (NYSE:GKOS) paid $16.6 million for a two-floor, 40,000-square-foot office building that sits next to its Aliso Viejo headquarters. Glaukos acquired ...

99.0% of Glaukos shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 6.4% of Glaukos shares are held by insiders.

ALISO VIEJO, Calif., April 16, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of ...

Analysts have set 12-month price targets for Glaukos, revealing an average target of $170.86, a high estimate of $200.00, and ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases ...

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., April 09, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology ...

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Glaukos (GKOS) to $165 from $180 and keeps an Overweight rating on the shares. The firm notes shares of Glaukos are down ...

Stifel Nicolaus analyst Thomas Stephan maintained a Buy rating on Glaukos (GKOS – Research Report) today and set a price target of $140.00. Discover outperforming stocks and invest smarter with ...